CDT Equity Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CDT Equity Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($39.22M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($17.80M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($535.0K) | Mar 28, 2025 |
| FY2023 | Sep 30, 2023 | $2.63M | Apr 16, 2024 |
| FY2023 | Jun 30, 2023 | ($2.11M) | Apr 16, 2024 |
| FY2023 | Mar 31, 2023 | ($1.67M) | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | ($4.89M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($4.4K) | Mar 28, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($36.76M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($15.42M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($5.26M) | Mar 28, 2025 |
| FY2023 | Sep 30, 2023 | ($430.0K) | Apr 16, 2024 |
| FY2023 | Jun 30, 2023 | ($1.32M) | Apr 16, 2024 |
| FY2023 | Mar 31, 2023 | ($1.52M) | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | ($3.16M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($4.4K) | Mar 28, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.05M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $3.38M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $90.0K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $37.0K | Apr 16, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($15.56M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($9.68M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($7.73M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($2.27M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($6.0K) | Mar 28, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $51.0K | Mar 28, 2025 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.65M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $4.19M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $7.22M | Mar 28, 2025 |
| FY2023 | Jun 30, 2023 | $900.0K | Apr 16, 2024 |
| FY2023 | Mar 31, 2023 | $506.0K | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $5.0K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $213.1K | Mar 28, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.82M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $10.99M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $7.68M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $10.09M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $192.5K | Mar 28, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.17M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($6.79M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | ($457.0K) | Apr 15, 2026 |
| FY2023 | Jun 30, 2023 | ($14.51M) | Apr 16, 2024 |
| FY2023 | Mar 31, 2023 | ($12.02M) | Apr 16, 2024 |
| FY2024 | Dec 31, 2022 | ($10.09M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2021 | ($5.96M) | Apr 16, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($68.33M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($29.10M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($11.30M) | Mar 28, 2025 |
| FY2023 | Sep 30, 2023 | ($11.54M) | Apr 16, 2024 |
| FY2023 | Jun 30, 2023 | ($14.54M) | Apr 16, 2024 |
| FY2023 | Mar 31, 2023 | ($12.44M) | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | ($10.77M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($4.4K) | Mar 28, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.51M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $554.0K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $4.23M | Mar 28, 2025 |
| FY2022 | Dec 31, 2022 | $345.8K | Mar 28, 2023 |
| FY2022 | Dec 31, 2021 | $48.6K | Mar 28, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1,177) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (61,598) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 28, 2025 |
| FY2023 | Sep 30, 2023 | 0 | Apr 16, 2024 |
| FY2023 | Jun 30, 2023 | (1,053) | Apr 16, 2024 |
| FY2023 | Mar 31, 2023 | (835) | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Apr 16, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1,177) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (61,598) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (8) | Mar 28, 2025 |
| FY2023 | Sep 30, 2023 | 0 | Apr 16, 2024 |
| FY2023 | Jun 30, 2023 | (1,053) | Apr 16, 2024 |
| FY2023 | Mar 31, 2023 | (835) | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Apr 16, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 92,140 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 461 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 738,295 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 64.63M | Apr 16, 2024 |